Humana HUM
Healthcare · Medical - Healthcare Plans · Synthos Deep Dive · 2026-07-03
The Overview
Humana is one of the biggest sellers of Medicare Advantage — the private version of Medicare that older Americans buy. The government grades these plans with a "Star Rating," and those stars control how much money the government pays the insurer. Humana's stars slipped, so its profit for 2026 is being cut roughly in half versus 2025. Management expects the stars and profits to recover over the next couple of years.
Here's the catch: the stock has already more than doubled in three months betting that the recovery happens. So you'd be paying up-front for a rebound that hasn't been delivered yet. That's why our verdict is Watch, not Buy — good company, real recovery story, but the easy money may already be made and the price sits above where our math says it's worth.
Here's what our three scores mean in everyday terms:
- Downside Risk 6/10 (a bit above average). The company is financially solid and the stock doesn't swing as wildly as the market — but after a huge run-up, if the recovery stumbles the fall could be sharp.
- Growth Quality 5/10 (middle). Revenue grows steadily, but profit margins are razor-thin and were just hammered by the government funding cut. This is not a high-quality-margin business.
- Exponential Potential 4/10 (low). What's coming is a bounce back to old profit levels, not a company that keeps getting exponentially bigger. It's a recovery, not a rocket.
The one big worry: if the Star Ratings and margins don't recover on schedule in 2027-2028, the whole reason the stock tripled disappears.
Putting a number on it: our fair-value estimate is $360 against a current price of $385.54 — a premium price for a business we still like.
Our summary metrics
Low beta (0.77) & investment-grade, but 45× FY26E adj EPS after a +124% 3-mo rip, thin GAAP margins, and a regulated-earnings cliff.
10% revenue growth but earnings collapsed on Star Ratings; a 2027-28 EPS recovery is the whole story and it is not yet in the bag.
Earnings *rebound* (not secular acceleration) — this is a mean-reversion trade, not an exponential; CenterWell is the only real growth engine.
What does “fair value” mean?
Fair value is Synthos’s estimate of what one share is worth today, based on our model of the company’s future cash generation and the risks to it. It is not a price target or a prediction of where the stock trades next quarter — it’s the price where we think risk and reward are balanced. Above it, you’re paying for outcomes better than our base case; below it, the market is offering a margin of safety.
The model’s inputs and weightings are proprietary — they’re the product. What we publish is the output, plus an independent, public-math cross-check further down the page (“Check our number”) so you can judge it for yourself.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Exponential Potential
Earnings *rebound* (not secular acceleration) — this is a mean-reversion trade, not an exponential; CenterWell is the only real growth engine.
What could take this further than the base case — and where the market may be underpricing it. Full forward-growth and acceleration math in Deeper analysis, §4 below.
Deeper analysis
Technicals, fundamentals, valuation, and the full expert-claim evidence panel — the detail behind the numbers above.
Reference table
| Street consensus | $298.50 (high $441 / low $195; 14 Buy · 28 Hold · 2 Sell → Hold) — the price has run past the Street's target |
| Valuation | 42× trailing GAAP EPS · 45× FY26E adj · 25× FY27E · 15× FY28E · 11× FY30E · EV/S 0.44× · EV/EBITDA 19.9× |
| Technicals | Strong uptrend — $396.75, −3% off 52-wk high, well above 50/200-DMA, RSI 65, +124% 3-mo (SPY +14%), but −29.5% max drawdown in the trailing year |
| Conviction | Low — 0 expert voices in the KB; the call rests entirely on fundamentals + quant |
| Position sizing | Watch / small tactical only — ≤1–2% if played, into weakness not strength |
What the experts actually said
No independent expert claims in the Synthos knowledge base yet for HUM — this dive is fundamentals- and technicals-driven, not panel-driven.
Price & moving averages 12 months · 50 & 200-day averages · 52-week range
Solid line = price · dashed line = 50-day average · dotted line = 200-day average · the two thin horizontal lines mark the 52-week high and low. Price above both averages is an uptrend.
Data summary: last close $385.54, 0% above the 50-day average ($385), 40% above the 200-day average ($276) — an uptrend. 6% below the 52-week high of $409, 136% above the 52-week low of $164.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Data summary: price $385.54 is currently inside the band (band $364–$399).
RSI (14) momentum gauge · 0–100
Above 70 (overbought zone, shaded) = overbought, below 30 (oversold zone, shaded) = oversold. Currently 52.
MACD 12 / 26 / 9 · trend & momentum
The MACD line crossing above the signal line (bars flip to the up color) = momentum turning up; crossing below (bars flip to the down color) = turning down. Bar height = the size of that gap.
Data summary: MACD is currently above its signal line by 0.77, positive momentum.
Relative performance vs S&P 500 & its sector (XLV (sector)), set to 100 a year ago
Solid = HUM · dashed = S&P 500 · dotted = XLV (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
1. What it is
Humana Inc. (NYSE: HUM) is a Louisville-based health-and-well-being enterprise and one of the two largest Medicare Advantage (MA) insurers in the US (alongside UnitedHealth). It reorganized into two reporting segments: an Insurance segment (MA, stand-alone Part D prescription drug plans, Medicaid/state-based contracts, and TRICARE military) and CenterWell, its healthcare-services arm (senior-focused primary care clinics, home health, and pharmacy). Fiscal year ends December 31. It has ~65,700 employees and is led by CEO Jim Rechtin.
Revenue mix (FY2025, from filings):
- By segment (gross, before intersegment eliminations): Insurance $124.56B (~85%) · CenterWell $22.47B (~15%). Consolidated revenue was $129.66B. CenterWell is the faster-growing, value-based-care engine (Senior Primary Care patients +22% sequentially in Q1'26, aided by the MaxHealth acquisition); Insurance is the scale business whose economics are dictated by CMS funding and medical-cost trend.
- By geography: FMP provides no geographic segmentation — Humana is effectively an all-US business, which concentrates its fate in US Medicare policy (a structural risk, §11).
The business model is simple to state and hard to run: collect a per-member premium set largely by CMS, then pay members' medical claims. The gap between the two — the benefit ratio (claims ÷ premium) — is the whole game. In Q1'26 the consolidated benefit ratio was 89.4%, meaning ~89 cents of every premium dollar went straight back out as medical cost. A regulated, thin-margin, volume business.
2. The expert thesis — (no traceable coverage)
There is no expert coverage of HUM in the Synthos knowledge base: total_claims = 0, breadth 0, net conviction 0. No independent net-bullish or cautionary voice in our panel has published a traceable claim on Humana. In keeping with the house standard, we will not manufacture conviction we do not have.
What that means for this note: the verdict below is fundamentals- and quant-driven only — built from the filings, the analyst-estimate consensus (FMP), the SEC 8-K guidance, and our own scenario model. It carries Low conviction by construction, and readers should weight it accordingly relative to names where we have a broad, reconciled expert panel. Where the Street has a view, we cite it as context (14 Buy / 28 Hold / 2 Sell → Hold; price target consensus $298.50), not as our anchor.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
| Score | 0–10 | The read |
|---|---|---|
| Downside Risk (lower = safer) | 6 · Moderate-High | Low beta (0.77) and investment-grade balance sheet, but the stock has run +124% in 3 months to 45× FY26E adjusted EPS, net-debt/EBITDA is optically 3.2× (EBITDA depressed by the Q4'25 loss), and the earnings base is a regulated number that just got cut. A recovery miss de-rates it hard. |
| Growth Quality | 5 · Average | Revenue compounds ~10%/yr, but net margin is 0.8% TTM, ROE ~6%, and FY26 earnings roughly halved on the Stars headwind. CenterWell is genuinely good; the Insurance core is a thin, cyclical, policy-driven margin. |
| Exponential Potential | 4 · Low | The 2027-30 EPS ramp ($15.84 → $35.72) is a rebound to prior earnings power, not secular acceleration. At a $47.6B cap in a mature US MA market, this is mean-reversion, not a multibagger. |
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. Instead the cases bound the range, and the scores above summarize them.
| Case | Key assumptions | Fair value |
|---|---|---|
| Bull | Stars recovery lands early and clean; FY27 adjusted EPS beats toward ~$18–20 as the BY2026 headwind fully reverses; MA margins normalize and CenterWell scales. Market pays ~26–28× a normalizing FY27 number. | ~$500 (+26%) |
| Base (our anchor) | Recovery arrives but on schedule and messily — FY27E adjusted EPS ~$16 (consensus $15.84), and the market applies a ~22–23× multiple to a still-improving but regulated earnings stream. | ~$360 (−9%) |
| Bear | Stars/margin normalization slips a year, medical-cost trend runs hot, or CMS funding disappoints; FY27 EPS stalls near ~$12 and the multiple de-rates to ~18–19× as the recovery premium unwinds. | ~$230 (−42%) |
Synthos fair value = the base case, ~$360 (−9%), with the full $230–$500 span as the honest range. Note our base sits above the Street's $298.50 consensus target — because the Street's targets look stale against a stock that has already rallied to $397 — but below the current price, which is the point: the market has largely paid for the recovery in advance. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). HUM is neither — it is a regulated-earnings recovery:
- Forward growth (headline vs. reality): revenue CAGR FY25→FY30E is a modest ~9.4% ($129.7B → $203.0B). The eye-catching number is EPS: FY26E $8.85 → FY30E $35.72, a ~42% CAGR. But read it honestly — that "growth" is EPS climbing back out of a Star Ratings hole, not a business inflecting upward.
- Acceleration (the 2nd derivative): revenue growth is roughly flat-to-decelerating (+10% FY25 → ~+9% FY27E). The EPS "acceleration" is entirely a base effect — FY26 is artificially depressed. There is no secular demand acceleration here; MA is a mature, ~5%/yr-membership market.
- Room to run: at $47.6B market cap the name has room to re-rate if earnings normalize, but the US MA/Medicare TAM is large-and-mature, not a greenfield. The only genuinely expandable leg is CenterWell (value-based senior primary care + home health + pharmacy), which is scaling 20%+ but is only ~15% of revenue.
- Reinvestment runway: real but capital-light on the insurance side; CenterWell (clinics, MaxHealth acquisition) is where incremental capital goes.
Exponential Potential: Low (4/10). Own the thesis, if at all, as a mean-reversion / margin-recovery idea — not as a compounding exponential. The honest framing: the upside is getting back to old earnings power, and the market has already priced much of that in.
5. Financials (real numbers — FMP annual/quarterly + 8-K)
- Revenue: FY25 $129.66B, +10.1% (FY24 $117.81B, +10.7% on FY23 $106.44B). Steady double-digit top-line growth driven by MA membership and per-member premium (CMS benchmark funding + IRA Part D subsidy).
- The earnings collapse (the whole story): GAAP net income fell to $1.19B in FY25 (GAAP EPS $9.84) from $1.21B FY24 and $2.49B FY23. FY25 GAAP was hit by impairments and a business-exit loss; adjusted EPS was $17.14 FY25. Management guides FY26 adjusted EPS "at least $9.00" — roughly a halving — driven by the Bonus-Year-2026 Star Ratings revenue headwind.
- Quarterly volatility (why "TTM" is misleading): Q1'26 GAAP EPS $9.83 (adjusted $10.31) but Q4'25 was a loss of −$6.61 GAAP (EBITDA −$685M) on year-end charges. The benefit ratio ran 89.4% in Q1'26 vs 87.0% a year earlier — the margin squeeze is visible and real.
- Margins: gross 14.0% TTM, EBITDA 2.1%, net 0.8% TTM. These are structurally thin insurer margins, currently at a cyclical/regulatory low. ROE 6.2%, ROIC 3.2% — depressed.
- Cash flow: FY25 operating CF $921M, capex −$546M, FCF just $375M — weak, and down sharply from $2.39B (FY24) and $2.98B (FY23) as working capital and the earnings trough bit. Q1'26 operating CF improved to $1.25B (vs $331M Q1'25). FCF recovery is a key tell to watch.
- Balance sheet: total debt $12.94B, cash $4.20B, net debt $8.74B. Net-debt/EBITDA screens at 3.2× but that is distorted by the trough EBITDA; debt-to-total-cap is 43%, investment-grade (FMP letter rating B, overall score 3/5). Serviceable, but the debt-to-equity score is the weakest component (1/5).
6. Valuation — priced in or room?
The honest read: HUM is not cheap on the earnings you can see today, and its cheapness on out-year numbers depends entirely on the recovery arriving.
- On trailing GAAP EPS ($9.87) the stock is ~42×. On FY25 adjusted EPS ($17.14) it is a more reasonable ~23× — but FY26 adjusted EPS is guided down to "at least $9.00," which puts the forward multiple at ~44× on the year you're actually buying.
- The bull's entire valuation case is the out-years: FY27E $15.84 (25×), FY28E $26.34 (15×), FY30E $35.72 (11×). If those hit, the stock is cheap. If the recovery slips, you are paying 44× for a still-shrinking year.
- EV/EBITDA 19.9× and EV/Sales 0.44× — the EV/Sales looks optically tiny, but that's just the low-margin insurer model; it is not a value signal. Price/book 2.6×.
- Street targets (context): consensus $298.50 (high $441, low $195, median $264.50) — the current $396.75 price is already 33% above the consensus target, a sign the stock has run ahead of where sell-side models sit. That is a caution flag, not a green light.
Verdict on valuation: this is a "recovery-priced" stock, not a value buy. You are underwriting the 2027-28 normalization at today's price. Our base-case FV (~$360) sits below the current price precisely because that recovery is largely in the price already.
7. Technicals (computed from EOD price history)
- Trend: strongly up. $396.75 sits far above the 50-DMA ($314) and 200-DMA ($253), with the 50 above the 200 (golden-cross posture). MACD +23.2 (positive).
- Location: just −3.1% off the 52-week high ($409) and a remarkable +142% off the 52-week low ($164). But the trailing-year max drawdown was −29.5% — this name whipsaws hard.
- Momentum: RSI(14) 65 — strong, approaching but not yet overbought (<70). After a +124% three-month move, momentum is stretched even if not technically overbought.
- Relative strength: HUM +124% 3-mo vs SPY +14% / QQQ +22%, and +57% 12-mo vs SPY +21%. Explosive recent outperformance — which is exactly why the risk/reward at this level is less attractive than it was at the lows.
- Read: technicals confirm a powerful recovery rally, but they also flag that the easy, high-conviction entry was months and ~100% ago. A technical buyer chasing here is late; a patient one waits for a pullback toward the rising 50-DMA (~$314).
8. Moat & competitive position
Humana's competitive position rests on scale in Medicare Advantage — it is the #2 MA carrier, with deep CMS relationships, a national provider network, and an increasingly vertically integrated CenterWell (owning primary care, home health, and pharmacy lets it manage medical cost internally). That vertical integration is a genuine, if modest, moat: it mirrors UnitedHealth's Optum playbook.
But the moat has hard limits: revenue is regulated (CMS sets the funding, Star Ratings gate the bonus payments), the product is substitutable (seniors can switch plans annually), and the margin is thin and cyclical. The Star Ratings stumble that drove the FY26 profit halving is itself the clearest evidence that this "moat" does not protect earnings from policy and execution shocks.
Peer set (FMP-listed, market cap): the closest true comp is Centene ($33.5B), the other large government-program insurer in the list. The rest of FMP's peer basket — Agilent ($36.9B), Alcon, GE HealthCare, Haleon, Insmed, IQVIA, Mettler-Toledo, BeOne, ResMed — are healthcare names but not managed-care comps; the more relevant real-world peers are UnitedHealth, Elevance, CVS/Aetna, and Cigna, which are not in this basket. Read the peer table with that caveat.
9. Management, capital allocation & guidance
- Capital allocation: dividend (FY25 $3.54/share, ~0.9% yield, ~38% payout of GAAP EPS) plus modest buybacks (only $151M repurchased FY25, down sharply from prior years — conserving capital through the trough). Incremental capital is going into CenterWell (the MaxHealth acquisition added ~59,000 patients and 54 centers). Sensible, defensive capital posture for a company in an earnings trough.
- Insider activity: the recent Form 4s are routine equity-award grants (May 2026 annual RSU/stock awards to the CEO, CFO, and officers), not open-market discretionary buying or selling. No signal either way.
- Leadership transition: Insurance Segment President George Renaudin retires June 29, 2026; Aaron Martin steps up to lead the Insurance segment — a planned, telegraphed transition of the most important P&L at exactly the moment execution matters most. Worth monitoring.
- Management's own guidance (half-weighted — their self-interested words): the Q1'26 8-K earnings release (filed 2026-04-29) affirmed FY26 adjusted EPS guidance of "at least $9.00" and revised GAAP EPS guidance to "at least $8.36" (from "at least $8.89"). Management explicitly frames the FY26 adjusted-EPS decline as "a result of the Star Ratings headwind for Bonus Year 2026, net of mitigation," and affirmed a FY26 Insurance benefit-ratio guide of 92.75% ± 25 bps and ~25% individual-MA membership growth. Q1'26 benefit ratio (89.4%) came in "slightly favorable" to their "just under 90 percent" guide. Treat this as management talking its own book: it confirms the size of the 2026 hole and their expectation that mitigation and membership growth set up the recovery — but it is guidance, not a result.
10. Catalysts & what to watch
- Next earnings: 2026-07-29 (Q2'26; Street EPS $6.97, revenue ~$40.6B). Watch the benefit ratio vs the 92.75% full-year guide and any commentary on 2027 Star Ratings trajectory.
- 2026 Star Ratings release (fall 2026): the single most important catalyst — the ratings published this autumn set the Bonus Year 2027 funding and are the linchpin of the entire recovery thesis.
- Annual Election Period (Oct–Dec 2026): MA membership retention/growth for the 2027 plan year; management is guiding ~25% individual-MA growth for 2026.
- CenterWell scaling: Senior Primary Care patient growth and margin — the one true secular growth leg.
- Medical-cost trend: the industry-wide utilization backdrop; a hot trend would pressure the benefit ratio and the recovery.
Thesis tripwires (what would change the call): a weak 2026 Star Ratings release; benefit ratio running above the 92.75% guide; a medical-cost-trend surprise; or the FY27 adjusted-EPS recovery being pushed out. Any of these unwinds the recovery premium now embedded in a $397 stock.
11. Key risks
- The recovery is regulated and unproven (structural): the entire multi-year EPS ramp depends on Star Ratings normalizing and CMS funding cooperating. This is not within management's full control.
- Valuation / de-rating: at 44–45× FY26E adjusted EPS after a +124% three-month run, and 33% above the Street's price-target consensus, there is little margin for error.
- Thin, cyclical margins: net margin 0.8% TTM; small moves in the benefit ratio swing earnings violently (see the Q4'25 GAAP loss).
- Policy concentration: ~all-US, ~85% Insurance revenue tied to Medicare/Medicaid — fully exposed to CMS rate-setting, Star methodology changes, and drug-pricing/IRA policy.
- Execution during a leadership transition: the Insurance segment changes leaders (June 2026) mid-recovery.
- No expert coverage / low conviction: with zero KB claims, this call lacks the independent-panel corroboration that anchors our higher-conviction names.
12. Verdict, position sizing & monitoring
Watch. Humana is a real, investment-grade #2 Medicare Advantage franchise with a genuine value-based-care growth engine in CenterWell, and its 2027-28 earnings-recovery story is plausible. But three things hold us at Watch rather than Buy: (1) the stock has already tripled off its lows (+124% in three months) and trades ~33% above the Street's price-target consensus, so the recovery is largely paid for; (2) our own base-case fair value (~$360) sits below the current $397 price; and (3) there is zero expert coverage in the KB, so we have no independent corroboration and the call is low-conviction by construction.
- Sizing: if played at all, tactical and small (≤1–2%), and into weakness (a pullback toward the rising 50-DMA ~$314), not into this strength. This is not a core holding.
- Monitoring: re-underwrite on the fall-2026 Star Ratings release and each earnings print; the tripwires in §10 govern the call.
- Single biggest risk: the 2027 Star Ratings + margin recovery fails to arrive on schedule — the entire reason the stock re-rated evaporates.
This verdict is logged as a tracked Synthos call as of 2026-07-03 at $396.75.
Provenance & disclosures
- Traceability: 0 KB claims, breadth 0 — there is no expert coverage of HUM in the Synthos knowledge base. This note is explicitly fundamentals- and quant-driven; no conviction is claimed beyond the data. Fabricated conviction is structurally impossible (claim-ID reconciliation), and here there are simply no claims to cite.
- Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates & prices 2026-07-02/03 · management guidance from the 2026-04-29 8-K (Item 2.02). Forward figures are analyst consensus (FMP) or management guidance, labeled as estimates throughout.
- Estimate caveat: FMP consensus EPS mixes GAAP and adjusted conventions across years; FY26E ($8.85) aligns with GAAP-style guidance, while out-year figures reflect an assumed adjusted-earnings recovery. Treat the EPS path as directional, not precise.
- Management caveat: FY26 guidance ("at least $9.00" adjusted / "at least $8.36" GAAP) is management's own, self-interested book — half-weighted by design.
- Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
- Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").